Theravance Biopharma News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

01.06.21	Theravance Biopharma-Aktie: Einschätzungen und Kursziele der Analysten im Mai (finanzen.net)
01.06.21	So schätzen Analysten die Theravance Biopharma-Aktie ein (finanzen.net)
02.05.21	Ausblick: Theravance Biopharma veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net)
21.02.21	Ausblick: Theravance Biopharma legt Zahlen zum jüngsten Quartal vor (finanzen.net)
30.11.20	So stuften die Analysten die Theravance Biopharma-Aktie im vergangenen Monat ein (finanzen.net)
05.08.20	Ausblick: Theravance Biopharma gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net)
05.05.20	Ausblick: Theravance Biopharma veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net)
29.02.20	So schätzen die Analysten die Zukunft der Theravance Biopharma-Aktie ein (finanzen.net)
23.02.20	Ausblick: Theravance Biopharma informiert über die jüngsten Quartalsergebnisse (finanzen.net)
29.07.19	Ausblick: Theravance Biopharma legt Quartalsergebnis vor (finanzen.net)
05.05.19	Ausblick: Theravance Biopharma stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net)
24.02.19	Ausblick: Theravance Biopharma stellt Zahlen zum jüngsten Quartal vor (finanzen.net)
10.11.18	Week Ahead In Pharmaceuticals: 13 Stocks To Watch (EIDX, NOVN, ZYME...) (RTTNews)
04.11.18	Ausblick: Theravance Biopharma stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net)
29.10.18	Biotech Stocks Facing FDA Decision In November (RTTNews)
11.10.18	Theravance, Mylan Report Positive New Data From Multiple Studies Of Yupelri (RTTNews)
08.10.18	Theravance Biopharma And Mylan To Present Data From Studies Of YUPELRI (RTTNews)
17.09.18	Theravance Reports Positive Data From Phase 3 Program For YUPELRI Solution (RTTNews)
15.09.18	Week Ahead In Pharmaceuticals: 7 Stocks To Watch (CMRX, VRNA, NITE...) (RTTNews)
12.09.18	FOMX Soars On Acne Trial Data, GLPG Abuzz, ACRX To Face FDA Panel In Oct. (RTTNews)
21.07.18	Week Ahead In Pharmaceuticals - 14 Stocks To Watch (LCI, INSY, TBPH...) (RTTNews)
06.06.18	Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018 (PR Newswire)
29.05.18	Theravance Biopharma Highlights Submission of Regulatory Application in Japan for Once-Daily Single Inhaler Triple Therapy FF/UMEC/VI for Patients with COPD (PR Newswire)
17.05.18	Theravance Biopharma to Host Key Opinion Leader Event Focused on the Unmet Medical Need in the Treatment of Neurogenic Orthostatic Hypotension (PR Newswire)
10.05.18	Theravance Biopharma to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference (PR Newswire)
08.05.18	Theravance Biopharma, Inc. Reports First Quarter 2018 Financial Results and Provides Business Update (PR Newswire)
01.05.18	Theravance Biopharma to Report First Quarter 2018 Financial Results on May 8, 2018 (PR Newswire)
25.04.18	Theravance Biopharma Highlights Approval of Expanded Indication in the US for Once-Daily Trelegy Ellipta for Treatment of COPD Patients (PR Newswire)
23.04.18	Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID™ Conference (PR Newswire)
20.04.18	Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) (PR Newswire)
19.04.18	Theravance Biopharma Highlights Landmark IMPACT Study Published in NEJM Showing Significant Benefits of Trelegy Ellipta for COPD Patients (PR Newswire)
17.04.18	Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID™ Conference (PR Newswire)
21.03.18	Theravance Biopharma to Present at the 17th Annual Needham Healthcare Conference (PR Newswire)
27.02.18	Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update (PR Newswire)
23.02.18	Aerkomm Inc. Appoints James J. Busuttil to its Board of Directors (PR Newswire)
20.02.18	Theravance Biopharma to Report Fourth Quarter and Full Year 2017 Financial Results on February 27, 2018 (PR Newswire)
15.02.18	Theravance Biopharma Highlights Submission of Landmark IMPACT Data to EMA to Support Expanded Label for Trelegy Ellipta (PR Newswire)
08.02.18	MobileIron Announces Strong Fourth Quarter 2017 Results (PR Newswire)
08.02.18	TBPH Inks $1Bln Deal, SGMO Hits Yearly High, ANAB Is Back Again (RTTNews)
07.02.18	Theravance Biopharma Enters Global Collaboration with Janssen for TD-1473 in Inflammatory Intestinal Diseases (PR Newswire)
30.01.18	ARDM Chokes, ABEO On Track, MASI Gets FDA Nod, ALBO Up 50% YTD (RTTNews)
29.01.18	Theravance Biopharma And Mylan Announce FDA Acceptance Of NDA For Revefenacin (RTTNews)
29.01.18	Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease (PR Newswire)
29.01.18	Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease (PR Newswire)
28.11.17	Theravance Biopharma Highlights Submission of Landmark IMPACT Data to FDA to Support Expanded Label for Trelegy Ellipta (PR Newswire)
21.11.17	Theravance Biopharma to Present at Two Upcoming Investor Conferences (PR Newswire)
16.11.17	Theravance Biopharma Highlights Marketing Authorization in Europe for Trelegy Ellipta as Once-Daily Single Inhaler Triple Therapy for the Treatment of COPD (PR Newswire)
13.11.17	Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease (PR Newswire)
13.11.17	Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Theravance Biopharma Inc When Issued

Aktien Top/Flop

Meistgelesene Nachrichten